The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Nothing is Everything.

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)1

Nothing less than the opportunity
to reach for their treatment goals

For your patients,
that’s everything.

SUSTAINED
RELIEF IN JOINTS AND SKIN

  • ACR20 primary endpoint met at Week 241-3
  • ACR50/70 and PASI 90 response rates at Week 241-3
  • Response rates observed up to ~4 years4,5
SEE SUSTAINED RELIEF IN JOINTS
SEE SUSTAINED RELIEF IN SKIN

SAFETY
AND TOLERABILITY

  • Up to 5 years of PsA safety data and ~9 years in Ps6*
  • Discontinuation rates evaluated at Week 24 and 5 years in PsA2,3,6
  • Safety profile of PsA at Week 24 was generally consistent with Ps at Week 161

 

MORE ABOUT SAFETY AND TOLERABILITY

SIMPLE
TO START

  • Quarterly dosing after 2 initiation doses at Weeks 0 and 4 (150 mg/dose) with 2 administration options1
  • No routine lab monitoring required during treatment after initial evaluation for tuberculosis (TB). Instruct patients to report signs and symptoms of infection1
  • Follow administration instructions and properly train PsA patients to start1
SEE DOSING AND ADMINISTRATION

*Includes 4 PsA Phase 2-3 studies (including KEEPsAKE 1 and KEEPsAKE 2). Includes 21 Phase 1-4 studies in Ps encompassing 6 trials using integrated data evaluated at Week 16 (including UltlMMa-1, UltlMMa-2, IMMhance, IMMvent, and IMMpulse) and 15 additional trials including LIMMitless.6

Make Skyrizi your first choice

START SKYRIZI AS A FIRST-LINE PsA TREATMENT OPTION AFTER NSAIDs OR csDMARDs1,7

SKYRIZI IS COVERED AS A 

FIRST-LINE ADVANCED THERAPY‡

WITH NO REQUIREMENT OF PRIOR BIOLOGIC

With 99%

PREFERRED COMBINED COMMERCIAL AND MEDICARE PART D COVERAGE FOR PsA8§||

National Commercial and Medicare Part D Formulary coverage under the pharmacy benefit as of January 2025.

‡Advanced therapies consist of PDE4is, TNFis, and other biologics.

§SKYRIZI is on a preferred tier or otherwise has preferred status on the plan's formulary.

||Coverage requirements and benefit designs vary by payer and may change over time. 

Please consult with payers directly for the most current reimbursement policies.

WHAT MAY AFFORDABILITY MEAN FOR YOUR PATIENTS?

$0

Eligible, commercially insured patients may pay as little as $0 per dose, four times a year

Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit SKYRIZISavingsCard.com or call 1.866.SKYRIZI for additional information. To learn about AbbVie's privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy

VIEW COVERAGE AND ACCESS

NO CHARGE FOR ELIGIBLE, COMMERCIALLY INSURED PATIENTS EXPERIENCING INITIAL INSURANCE DENIAL FOR UP TO 24 MONTHS**

Download or email Skyrizi Complete Enrollment and Prescription Form

DOWNLOAD
EMAIL

**Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.